[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 849
Citations 0
Correction
August 6, 2019

Incorrect Description of Drug Act

JAMA. 2019;322(5):469. doi:10.1001/jama.2019.10338

In the Viewpoint entitled “The Orphan Drug Act Revisited,”1 published in the March 5, 2019, issue of JAMA, there was incorrect wording used to describe the Orphan Drug Act. In all instances, “patent protection” and “patent exclusivity” should have read “market exclusivity.” The sentences should have read as follows: “To promote the development of orphan drug therapies, the ODA provided companies that engaged in research for drugs with populations of fewer that 200 000 patients with tax incentives, research substudies, and extended market exclusivity”; “These impressive revenues do not consider the substantial financial incentives companies receive in fee waivers and extended market exclusivity”; and “Another possibility would be to enact price regulations for orphan drugs after their extended market exclusivity expires, if no generic competition has arisen.” This article was corrected online.

References
1.
Thomas  S, Caplan  A.  The Orphan Drug Act revisited.  JAMA. 2019;321(9):833-834. doi:10.1001/jama.2019.0290PubMedGoogle ScholarCrossref
×